

From: [Seville, Tyler](#)
To: [AGO - High Cost Prescription Drugs](#)
Cc: [Fitzsimmons, Tricia](#); [Guilbault, Matthew](#)
Subject: CORRECTION: Notice of Introduction of New High-Cost Prescription Drugs - Tabrecta
Date: Friday, May 8, 2020 3:32:46 PM

EXTERNAL SENDER: Do not open attachments or click on links unless you recognize and trust the sender.

To the Office of Attorney General:

Pursuant to 18 V.S.A. § 4637 (Notice of Introduction of New High-Cost Prescription Drugs), effective July 1, 2018, when a prescription drug manufacturer introduces a new prescription drug to market at a wholesale acquisition price above the threshold set for a specialty drug under the Medicare Part D program, that manufacturer is required to provide certain written information to the Attorney General's Office.

Per section (2)(b) of § 4637 Notice Of Introduction Of New High-Cost Prescription Drugs, Novartis is notifying the Office of the Attorney General in the state of Vermont the Wholesaler Acquisition Cost (WAC) within 3 calendar days following the release of Tabrecta® into the commercial market. Please see table below:

NDC	Drug Product Description	Introduction to Market	WAC at Introduction
0078-0716-56	Tabrecta (capmatinib) 56 tabs of 200mg	May 6, 2020	\$8,975.00
0078-0709-56	Tabrecta (capmatinib) 56 tabs of 150mg	May 6, 2020	\$8,975.00

On May 6, 2020, Novartis announced that the US Food and Drug Administration (FDA) approved Tabrecta™ (capmatinib, formerly INC280), an oral MET inhibitor for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to MET exon 14 skipping (METex14) as detected by an FDA approved test.

Please feel free to contact me if you have any questions and/or require any additional information.

Regards,
Tyler

Tyler Seville
Associate Director, Policy Reporting
1-856-577-4824
Tyler.seville@novartis.com

Novartis Services, Inc.
North America Public Affairs
One Health Plaza
Building 200, Office 720
East Hanover, NJ 07936-1080

USA